The European Medicines Agency's Committee For Medicinal Products For Human Use Has Adopted A Positive Opinion Recommending Abbvie's Atogepant For The Prophylaxis Of Migraine In Adults Who Have Four Or More Migraine Days Per Month
Portfolio Pulse from Benzinga Newsdesk
The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended AbbVie's Atogepant for the prophylaxis of migraine in adults with four or more migraine days per month.
June 23, 2023 | 12:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AbbVie's Atogepant receives positive recommendation from EMA's Committee for migraine prophylaxis in adults.
The positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use for AbbVie's Atogepant is a significant step towards approval in Europe. This could lead to increased sales and revenue for AbbVie, positively impacting its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100